EFB announces clinical results for Cerebraca® Wafer at ASCO 2026
The wafer showed potential to reverse chemoresistance and a Phase IIb/III trial has started.
Latest Everfront Biotech News & Updates
See the latest news and media coverage for EFB. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
Latest news about Everfront Biotech (EFB)
In short: EFB presented clinical trial data for its Cerebraca Wafer glioblastoma treatment and advanced the candidate into global Phase IIb/III trials.
Company announcements
Everfront Biotech presents updated Cerebraca Wafer results at SNO 2025
The e-poster covers Phase I/IIa trial data for Recurrent Glioblastoma treatment and Phase IIb/III plans. No drug-related adverse effects reported.
Everfront Biotech presents Cerebraca® Wafer trial results at CNS meeting
Phase I/IIa trial shows 15.7 months median survival, no serious adverse events. Plans global Phase IIb trial launch late 2025.
Everfront Biotech unveils Cerebraca® Wafer trial results
Dr. Jen-Wei Liu presents Phase I/IIa outcomes at 2024 Taiwan Healthcare+ Expo, showing 26.2 months median survival and no direct side effects.
Media coverage
Everfront Biotech Files for Proposed IPO
Everfront Biotech (EFB) has filed for a proposed IPO. The company describes itself as: "We are a clinical stage biopharmaceutical company dedicated to the discovery...
Never miss news about EFB
Track EFB and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Fujitsu
Kennedy Wilson
CervoMed
Eoptolink
Ligent
InnoLight
Nauticus Robotics
Regentis Biomaterials
Clearfield
IMC
Helical Fusion
BDO
PwC
Icertis
Deloitte
Execo
Grant Thornton
Aktis Oncology
GEODNET
Moxie
Onorato
Aloe Care
Tombot
CarePredict
Labrador
Joy for All
Intuition Robotics
temi
Rocket55
Kreativ HQ
NATIV3
Snap Agency
The Guerrilla
ArcStone
Hook